Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
19.8M
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
603K
-
Shares change
-
+224K
-
Total reported value, excl. options
-
$1.09M
-
Value change
-
+$396K
-
Number of buys
-
14
-
Number of sells
-
-13
-
Price
-
$1.81
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q2 2025
39 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 603K shares
of 19.8M outstanding shares and own 3.05% of the company stock.
Largest 10 shareholders include OAKTREE CAPITAL MANAGEMENT LP (241K shares), Murchinson Ltd. (80.6K shares), Oaktree Fund Advisors, LLC (42.9K shares), UBS Group AG (39.9K shares), GEODE CAPITAL MANAGEMENT, LLC (28.2K shares), JONES FINANCIAL COMPANIES LLLP (26K shares), HighTower Advisors, LLC (24.6K shares), XTX Topco Ltd (23.4K shares), Beacon Pointe Advisors, LLC (18.8K shares), and VANGUARD GROUP INC (18.8K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.